Loading
A phase 2 trial of Fludarabine, Cyclophosphamide in non-hodgkin lymphoma, run by Celgene, active and no longer recruiting.
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) is a phase 2 interventional study registered as NCT04245839 by Celgene, with 276 participants planned, started 2020-07-14 and due to reach its primary completion in 2031-09-30. Interventions recorded: Fludarabine, Cyclophosphamide, JCAR017. Conditions listed: Lymphoma, Non-Hodgkin. No results are recorded here; the registry entry is the source.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.